Influence of comorbidity on the survival of patients with lung cancer
Abstract
Background: The aim of the study was to establish the comorbidity in the presented group of lung cancer patients and to examine the applicability of CI by determining the difference of survival rate according to CI.
Methods: In 259 non-small cell lung cancer patients, median age 65, primarily treated nonsurgically (radiotherapy 187, radio- and chemotherapy 6, radiotherapy and interferon 3, chemotherapy 2, simptomatically 27, unknown 34), clinical stage IA in 9, IB in 51, IIA in 1, IIB in 61, IIIA in 116, IIIB in 14 and IV in 7 patients, the comorbidity and the survival rate according to CI were established.
Results: No comorbidity was established in 66 (25.5 %) of patients, CI 1 in 121 (46.7 %), CI 2 in 54 (29.8 %), CI 3 in 14 (5.4 %), CI 4 in 3 (1.2 %), and CI 5 in 1 (0.4 %) patient. The majority (146 patients) had pulmonary disease, followed by cardiovascular disease (40 patients), other conditions were rarely observed. Median survival of CI 0 patients was 13.3 months, CI 1 patients 11.1 months, CI 2–5 patients 9.9 months. The survival difference was statistically significant (p = 0.0351).
Conclusions: Most of the lung cancer patients had also other pulmonary and cardiovascular diseases. The survival rate was significantly different according to the established CI. This way the usefulness of CI for determining the comorbidity in non-small cell lung cancer patients was confirmed.
Downloads
References
Mannino DM, Ford E, Giovino GA, Thun M. Lung cancer deaths in the United States from 1979 to 1992: an analysis using multiple- cause mortality data. Int J Epidemiol 1998; 27: 159–66.
De Rijke JM, Schouten LJ, ten Velde GP, Wanders SL, Bollen EC, Lalisang RI, et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 2004; 46: 233–45.
Gridelli C. Chemotherapy in elderly patients. Lung Cancer 2005; 49 Suppl 3: S42–3.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in the longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–83.
Debevec L, Eržen J, Debeljak A, Crnjac A, Kovač V. Exploratory thoracotomy and its influence on the survival of patients with lung cancer. Wien Klin Wochenschr 2006; 118: 479–84.
Sobin LH, Witekind CH, eds. UICC. TNM classification of malignant tumors. New York: Wiley-Liss; 1997. p. 91–7.
Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453–71.
De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbiditya a critical review of available methods. J
Clin Epidemiol 2003; 56: 221–9.
Tammenagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer 2003;103:792– 802.
Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 1047–57.
Tammenagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 2004; 57: 597–609.
Birim O, Maat AP, Kappetein AP, van Meerbeeck JP, Damhuis RA, Bogers AJ. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg 2003; 23: 30–4.
Moro-Sibilot D, Aubert A, Diab S, Lantuejoul S, Fourneret P, Brambilla E, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J 2005; 26: 480–6.
Battafarano RJ, Piccirillo JF, Meyers BF, Hsu HS, Guthrie TJ, Cooper JD, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 125: 444–5.
Birim O, Kappetein AP, Bogers AJ. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiovasc Surg 2005; 28: 759–62.
Lundbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community- based population analysis. Int J Radiat Oncol Biol Phys 2003; 55: 1321–30.
Lopez-Encuentra A, Bronchogenic Carcinoma Co-operative Group. Comorbidity in operable lung cancer. A multicenter descriptive study on 2992 patients. Lung Cancer 2002; 35: 263–9.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
